Sign inJoin waitlistJoin the waitlist

Uday Popat

Deputy Department Chair Ad Interim · University of Texas M D Anderson Cancer Center

Credentials: · · · · ·

History

University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

Internal Medicine
Baylor College of Medicine
1997–1999
Hematology and Medical Oncology
Baylor College of Medicine
1996–1997
Bone Marrow Transplantation
University of Texas M D Anderson Cancer Center
1995–1996
Royal Free Hospital and School of Medicine University of London
1994–1995
Royal Free Hosp & School of Med
1991–1994
Grimsby District General Hospital and University Hospital Nottingham
1990–1991
University of Bombay
1983–1988
Doctor of Medicine
1984–1988

Research

Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
Nature Medicine · 2024 · 428 citations
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells
Journal of Clinical Investigation · 2016 · 410 citations
Cord-blood engraftment with ex vivo mesenchymal-cell coculture
New England Journal of Medicine · 2012 · 371 citations

Richard Champlin
283 papers
Elizabeth Shpall
200 papers
Chitra Hosing
198 papers
Partow Kebriaei
174 papers
Muzaffar Qazilbash
165 papers
Amin Alousi
157 papers · 2 as a fellow
Betul Oran
129 papers · 3 as a resident
Yago Nieto
119 papers
Qaiser Bashir
116 papers · 1 as a fellow
Issa Khouri
99 papers
Stefan Ciurea
90 papers
BA
Borje Andersson
80 papers

Clinical trials

A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2025–2030
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
Principal investigator · Recruiting · Phase 2
M.D. Anderson Cancer Center
2024–2029
Itacitinib for the Prevention of Graft Versus Host Disease
Principal investigator · Active not recruiting · Phase 2
M.D. Anderson Cancer Center
2022–2027
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
Principal investigator · Recruiting · Phase 2, Phase 3
M.D. Anderson Cancer Center
2021–2027